RNA Display Methods for the Discovery of Bioactive Macrocycles

Area of Science:

• Medicinal Chemistry
• Biotechnology
• Drug Discovery

Background:

• Macrocycles, particularly macrocyclic peptides, represent a promising class of de novo drug candidates.
• Traditional and challenging drug targets (e.g., protein-protein interactions) require novel therapeutic modalities.
• In vitro display systems and computational design have advanced cyclic peptide binder development.

Purpose of the Study:

• To review the development and applications of messenger RNA (mRNA) display technology for macrocyclic peptide drug discovery.
• To highlight the capabilities of mRNA display in generating high-affinity cyclic peptide ligands.
• To discuss the evolution, modifications, and future potential of mRNA display platforms.

Main Methods:

• mRNA display as a key platform technology for cyclic peptide ligand discovery.
• Cell-free transcription/translation systems enabling genetic reprogramming and modifications.
• High-throughput focused affinity maturation for hit-to-lead optimization.
• Engineering of mRNA-displayed peptides into chemical conjugates.

Main Results:

• mRNA display generates natural-product-like macrocyclic peptide binders with antibody-like affinities.
• The technology is highly evolvable through genetic and chemical modifications.
• Enables rapid hit-to-lead development and creation of peptide conjugates.

Conclusions:

• mRNA display is a leading strategy for discovering potent macrocyclic peptide therapeutics.
• The platform's versatility supports diverse drug discovery and development needs.
• Continued advancements in mRNA display promise to unlock the full potential of macrocyclic peptides as drugs.